BRAIN Biotech AG

DEM1103.HRB24758|Darmstädter Straße 34-36, 64673 ZwingenbergGermany|2000

Profit-€11.8M

Revenue€49.6M

Balance€66.3M

About

BRAIN AG is a Zwingenberg-based industrial biotechnology company focusing on nutrition, health, and the environment. The business model rests on two pillars: BioScience, which encompasses collaboration business with industrial partners, and BioIndustrial, which involves the development and marketing of proprietary products. The company utilizes a proprietary BioArchive containing over 53,000 characterized microorganisms and genetic libraries to identify new enzymes and natural substances. With 108 employees, BRAIN pursues a growth strategy characterized by strong research and development activities and the commercialization of biotechnological solutions.

Business purpose (commercial register)

die Identifizierung, Erforschung, Entwicklung, Herstellung und Vermarktung biologischer, biochemischer und biotechnologischer Verfahren und Produkte, insbesondere von Biokatalysatoren und anderen bioaktiven Naturstoffen für industrielle Anwendungen in Chemieunternehmen, für die Herstellung von Nahrungsmitteln, Kosmetika und Medizinprodukten, für die Abfall- und Schadstoffbeseitigung sowie für die Energie- und Rohstoffgewinnung, einschließlich der Entwicklung, Herstellung und Vermarktung solcher Verfahren und Produkte, die bioaktive Bestandteile enthalten, auf biotechnischen Mechanismen basieren, bioaktive Wirkungen entfalten oder biotechnische Anwendungen ermöglichen

ClassificationWZ 2025

N.72.10.1 - Forschung und Entwicklung im Bereich Biotechnologie

Business Sectors

Industriekooperationen7.348 TEUR(98.7%)

Sonstige Umsatzerloese98 TEUR(1.3%)

Products

Katalysatoren Wirkstoffe Süsswaren Naturstoffe Starterkulturen

Opportunities & Risks

Wundheilung Süsswaren Biotechnologie Wirkstoffe Innovation Nachhaltigkeit

Wachstum Forschung Haftungsrisiken Umwelt Patente Europa

This summary was generated with the help of AI. See our Data Quality Notice. Report error?

Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24758 (as of 2 October 2026)

Company Structure

Shareholders

Name	Type	City
Adriaan Moelker	Vorstand	Bad Homburg v. d. Höhe
Michael Schneiders	Vorstand	Frankfurt am Main

Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24758 (as of 2 October 2026)

Company History

Management

Date	Event Type	Event
06.06.2024	Registered Seat Change	AnalytiCon Discovery Zweigniederlassung
12.06.2023	Satzung amended	Satzung
15.04.2021	Company Name Change	BRAIN Biotech AG

Date	Type	Change	Total Capital
16.09.2021	Capital Increase	+1.986.135 €	21.847.495 €
05.06.2020	Capital Increase	+1.805.578 €	19.861.360 €
15.09.2017	Capital Increase	+1.641.434 €	18.055.782 €

Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24758 (as of 2 October 2026)

Financials

Key financial figures over time — BRAIN Biotech AG
Year	Revenue	Profit	Balance	Employees
2025	€49,623,000	-€11,833,000	€66,337,000	—
2024	€54,631,000	-€11,100,000	€88,737,000	—
2023	€55,335,000	-€8,114,000	€70,937,000	—
2022	€49,509,000	-€6,341,000	€77,992,000	—
2021	€38,389,000	-€4,680,000	€77,737,000	—
2020	€38,560,000	—	€72,150,000	—
2019	€27,051,000	—	€66,123,000	—
2018	€24,105,000	—	€74,464,000	—
2017	€22,790,000	—	€68,504,000	—
2016	€21,132,363	—	€47,511,976	—

Source: German Company Register (Unternehmensregister)

Register Files

Current Printout (AD)

Chronological Printout (CD)

Articles of Association

Registration Application

Source: German Commercial Register (Handelsregister) Darmstadt Local Court, HRB 24758 (as of 2 October 2026)

Contact

Website:brain-biotech.com

Email:Sign in to view

Similar Companies

MLM MEDICAL LABS GmbH

Mönchengladbach · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin

Stockert GmbH

Freiburg im Breisgau · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin

Foundation Medicine GmbH

Penzberg · Forschung und Entwicklung im Bereich Biotechnologie

Annual Financial Statements

Annual Report 2025Published on 23 January 2026

Consolidated Report 2025Published on 23 January 2026

Consolidated Report 2024Published on 10 February 2025

Annual Report 2024Published on 10 February 2025

Consolidated Report 2023Published on 1 February 2024

Annual Report 2023Published on 1 February 2024

Annual Report 2022Published on 3 February 2023

Consolidated Report 2022Published on 3 February 2023

Annual Report 2021Published on 22 February 2022

Consolidated Report 2021Published on 22 February 2022

Consolidated Report 2020Published on 2 March 2021

Annual Report 2020Published on 17 February 2021

Annual Report 2019Published on 25 February 2020

Consolidated Report 2019Published on 6 February 2020

Annual Report 2018Published on 14 February 2019

Consolidated Report 2018Published on 8 February 2019

Annual Report 2017Published on 28 February 2018

Consolidated Report 2017Published on 16 February 2018

Annual Report 2016Published on 20 February 2017

Consolidated Report 2016Published on 17 February 2017

Annual Report 2015Published on 25 January 2016

Annual Report 2014Published on 22 October 2015

Annual Report 2013Published on 7 January 2015

Annual Report 2012Published on 8 October 2013

Annual Report 2011Published on 5 October 2012

Annual Report 2010Published on 11 October 2011

Annual Report 2009Published on 27 October 2010

Annual Report 2008Published on 25 November 2009

Annual Report 2007Published on 31 October 2008

Source: German Company Register (Unternehmensregister)

Trends

Funding

Last Round

€12.8M

Series B · Mar 2025

Total

Rounds

Investors

Cost type	Amount	Share
Personnel Costs	€17,641,000	41.2%
Material Costs	€17,393,000	40.6%
Depreciation	€4,702,000	11.0%
Interest & Similar	€3,064,000	7.2%

BRAIN Biotech AG

About

Business purpose (commercial register)

ClassificationWZ 2025

Business Sectors

Products

Opportunities & Risks

Company Structure

Company History

Financials

Register Files

Contact

Similar Companies

Annual Financial Statements

Cost Distribution (2020)

Trends

Funding